Natesto (Testosterone) Patent Expiration, LOE Window & CMS Spending

Natesto (Testosterone) by Acerus: FDA Orange Book LOE 2034-03-17, 11 AB generics, $608K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAcerus
FDA Application & PathwayN205488 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-03-17
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$608K
2024 Medicare Part D Spend$490K
2024 Medicaid Spend$119K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel